Publications by authors named "Franziska Pieper"

Article Synopsis
  • The Omicron variant (B.1.1.529) of SARS-CoV-2 has many mutations that make it highly transmissible and partially able to evade neutralizing antibodies, but vaccinated individuals still have some protection against severe disease due to strong cellular immunity.
  • In a study involving healthcare workers who received three doses of the BioNTech mRNA vaccine, it was found that their B and T cell responses were enhanced against older variants but less effective against the Omicron spike protein.
  • Those previously infected with earlier variants (like Alpha) had reduced antibody responses against Omicron, while uninfected individuals who got infected with Omicron showed improved immunity to earlier variants but weaker responses against Omicron itself.
View Article and Find Full Text PDF

Anti tumour necrosis factor (anti-TNF) drugs increase the risk of serious respiratory infection and impair protective immunity following pneumococcal and influenza vaccination. Here we report SARS-CoV-2 vaccine-induced immune responses and breakthrough infections in patients with inflammatory bowel disease, who are treated either with the anti-TNF antibody, infliximab, or with vedolizumab targeting a gut-specific anti-integrin that does not impair systemic immunity. Geometric mean [SD] anti-S RBD antibody concentrations are lower and half-lives shorter in patients treated with infliximab than vedolizumab, following two doses of BNT162b2 (566.

View Article and Find Full Text PDF

SARS-CoV-2 infection results in different outcomes ranging from asymptomatic infection to mild or severe disease and death. Reasons for this diversity of outcome include differences in challenge dose, age, gender, comorbidity and host genomic variation. Human leukocyte antigen (HLA) polymorphisms may influence immune response and disease outcome.

View Article and Find Full Text PDF

The impact of the initial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infecting strain on downstream immunity to heterologous variants of concern (VOCs) is unknown. Studying a longitudinal healthcare worker cohort, we found that after three antigen exposures (infection plus two vaccine doses), S1 antibody, memory B cells, and heterologous neutralization of B.1.

View Article and Find Full Text PDF

American Foulbrood, caused by , is the most devastating bacterial honey bee brood disease. Finding a treatment against American Foulbrood would be a huge breakthrough in the battle against the disease. Recently, small molecule inhibitors against virulence factors have been suggested as candidates for the development of anti-virulence strategies against bacterial infections.

View Article and Find Full Text PDF

Understanding the nature of immunity following mild/asymptomatic infection with SARS-CoV-2 is crucial to controlling the pandemic. We analyzed T cell and neutralizing antibody responses in 136 healthcare workers (HCW) 16-18 weeks after United Kingdom lockdown, 76 of whom had mild/asymptomatic SARS-CoV-2 infection captured by serial sampling. Neutralizing antibodies (nAb) were present in 89% of previously infected HCW.

View Article and Find Full Text PDF

Pollination provided by managed honey bees as well as by all the wild bee species is a crucial ecosystem service contributing to the conservation of biodiversity and human food security. Therefore, it is not only the health status of honey bees but also the health status of wild bees that concerns us all. In this context, recent field studies suggesting interspecies transmission of the microsporidium parasite from honey bees () to bumblebees ( spp.

View Article and Find Full Text PDF